These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8678098)

  • 1. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections.
    Sharifi R; Geckler R; Childs S
    Am J Med; 1996 Jun; 100(6A):76S-82S. PubMed ID: 8678101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new therapeutic option for the treatment of pneumonia.
    McCabe R; Chirurgi V; Farkas SA; Haddow A; Heinz G; Greene S
    Am J Med; 1996 Jun; 100(6A):60S-67S. PubMed ID: 8678099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future management of serious skin and skin-structure infections.
    Schwartz R; Das-Young LR; Ramirez-Ronda C; Frank E
    Am J Med; 1996 Jun; 100(6A):90S-95S. PubMed ID: 8678103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
    Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of cefepime: a new extended-spectrum parenteral cephalosporin.
    Neu HC
    Am J Med; 1996 Jun; 100(6A):68S-75S. PubMed ID: 8678100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin.
    Segreti J; Levin S
    Am J Med; 1996 Jun; 100(6A):45S-51S. PubMed ID: 8678097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.
    Schrank JH; Kelly JW; McAllister CK
    Clin Infect Dis; 1995 Jan; 20(1):56-8. PubMed ID: 7727671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Levine DP; McNeil P; Lerner SA
    Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime as treatment for osteomyelitis and other severe bacterial infections.
    Jauregui L; Matzke D; Scott M; Minns P; Hageage G
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():141-9. PubMed ID: 8150758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
    Pfaller MA; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):273-6. PubMed ID: 9458985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.